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Opinion statement
Survivors of hematopoietic stem cell transplant (HSCT) are at significant risk for cardiac
disease and cardiac complications. While there may be cardiac complications during the
acute period of HSCT, long-term survivors remain at risk for cardiovascular disease at a rate
at least fourfold higher than the general population. Aggressive screening for cardiac risk
factors such as diabetes, hypertension, and arrhythmias is warranted pretransplant. For
those with risk factors, particularly a history of cardiovascular disease or atrial fibrillation,
cardiology consultation is warranted in the pretransplantation period. Aggressive screen-
ing for cardiac risk factors such as diabetes, hypertension, and hyperlipidemia is warranted
in HSCT survivors as well; early and aggressive treatment of left ventricular dysfunction is
warranted. Collaboration between hematology/oncology and cardiology through a cardio-
oncology clinic is an optimal way to help manage these patients.
Introduction
Hematopoietic stem cell transplantation (HSCT) is a
potential cure for various hematologic malignancies,
and rarely non-malignant conditions. Since 1980 when
HSCT first began as a lifesaving therapy, the number of
allogeneic transplantations has continuously risen with
over 320,000 individuals having received a stem cell
transplantation by 2013.[1] HSCT consists of the ad-
ministration of myelosuppressive chemotherapy with
or without total body irradiation followed by infusion
of a hematopoietic stem cell graft that induces an
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immunologic response on malignant cells. The prepar-
ative regimen and the immune response are the major
sources of treatment-related toxicity. Identifying patients
fit enough to tolerate such toxicity and anticipating and
managing expected complications are key aspects to
improving HSCT outcomes.
Acute cardiac complications
Cardiovascular disease and cardiovascular complications are one of the most
common complications associated with HSCT. These complications can occur
both acutely within the first 100 days as well as long-term, many years after the
initial transplantation period. Prior studies report that 9–27 % of persons
receiving HSCT develop arrhythmias,[2•] while other more recently published
single institutions have reported incidences as low as 1 %.[3] The most com-
mon arrhythmias include atrial fibrillation, atrial flutter, and supraventricular
tachycardia. Risk factors for the development of arrhythmias include the fol-
lowing: older age, prior anthracycline use, a lower ejection fraction at baseline,
history of arrhythmias, baseline renal dysfunction, and the presence of prema-
ture supraventricular complexes on baseline screening electrocardiogram.[4–6]
The effect of these arrhythmias on outcomes was largely unknown until a recent
publication evaluated the impact of arrhythmias on HSCT. In examining 104
out of 1177 individuals who underwent HSCT between 1999 and 2009, sub-
jects with an arrhythmia post transplant were more likely to have a longer
median hospital stay (32 vs 23 days, pG0.001), a greater probability of an
analysis, posttransplant arrhythmia was associated with a greater risk for death
within a year of transplant [OR 3.5 (2.1–5.9)]. These results have been con-
firmed in other studies in autologous HCT recipients. Of those treated between
2000 and 2006 who developed arrhythmias during the first 100 days post
transplantation, the risk of mortality was 40 % [5].
Other cardiac complications of HSCT include congestive heart failure
(CHF), cardiac tamponade, and ventricular arrhythmias resulting in death.[3]
While cardiac tamponade and ventricular arrhythmias are rare occurring in
G1 % of recipients, CHF remains a concern particularly as the age of individuals
undergoingHSCT increases. Most preparative regimens for allogeneic HSCT use
cyclophosphamide (CY). High-dose CY can induce myocardial necrosis which
clinically presents with dyspnea, tachycardia, hypotension, decreased QRS volt-
age on electrocardiogram, and pericardial effusion within ten days of drug
administration.[7–10] The histology in these cases shows a unique pattern of
fibrin microthrombi in capillaries, fibrin strands in the interstitium, and fibrin
strands inmyocytes.[11] Felt to be dose related with higher rates of heart failure
in those receiving doses ≥170 mg/m2,[7, 12] heart failure occurred in as many
as 28 % of cases of HSCT using older regimens with higher dose CY. With CY
dose reductions in contemporary regimens, heart failure appears less fre-
quent.[3, 7, 8, 11] Recent studies suggest congestive heart failure occurs G2 %
of the time.[13•]
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intensive care unit admission (52 vs 7 %, pG0.001), and greater probability of
death within 1 year of transplant (41 vs 15 %, pG0.001). In a multivariate
With an understanding of the greater therapeutic effect onmalignancy of the
immune response induced by the graft compared to the chemotherapy condi-
tioning, reduced intensity conditioning (RIC) regimens that spare some of the
toxicity of a myeloablative preparative regimen have been developed in recent
years.[14] Melphalan and fludarabine are agents used in some RIC regimens
that have been reported to cause cardiovascular complications. Melphalan, as
part of RIC or autologous HSCT regimens, has been associated with atrial
fibrillation, atrial flutter, and supraventricular tachycardia in up to 9 % of
cases.[5, 15–17] The combination of melphalan and fludarabine has been
reported in some case series to cause heart failure ranging in severity from
minor and reversible systolic dysfunction to fatal heart failure.[18–20] Cardio-
vascular complications thus should remain a consideration even for patients
undergoing RIC.
The development of RIC made HSCT a treatment option for patients with
comorbidities and who are older.[1, 21, 22] How to account for comorbidities
in the pretransplant evaluation and how to manage them during the transplan-
tation process remains a challenge for clinicians. Through the HSCT-specific
comorbidity index, a cardiac comorbidity (defined as the presence of coronary
artery disease, congestive heart failure, myocardial infarction, or an ejection
fraction G50 %) is considered as a low-risk comorbidity. Further, recent data
suggests that those with an ejection fraction G50 % can still be eligible for HSCT
and patients with borderline left ventricular systolic dysfunction can safely
undergo HSCT without alterations in overall survival or treatment-related
complications.[23] As the population ages and more and more transplants
are being done on individuals 965 years old which many have underlying
cardiovascular disease at baseline, a complete geriatric assessment (CGA) in
these patients may be beneficial.[24, 25] The CGA focuses not only on comor-
bidities but also includes assessments of dementia, delirium, failure to thrive,
incontinence, osteoporosis, falls, polypharmacy, and sarcopenia.[24–26] There
are little data available on the role of CGAs in the HSCT population; however,
this is quickly changing [27–29].
Long-term cardiac complications from HSCT
For those individuals who survive the first 100 days of HSCT, HSCT survivors
remain at an increased risk for cardiovascular complications many years after
transplantation.[13•, 30–33] Single institution studies suggest the 10-year cu-
mulative incidence of hypertension is 37.7 %, diabetes 18.1 %, hyperlipidemia
46.7 %, and having more than one of these cardiac risk factors at 31.4 %.[32]
Most of these risks are seen in allogeneic HSCT survivors with the risk being
highest in those at an older age, with obesity, and with a history of grade 2–4
acute graft-versus-host disease. The risk of cardiovascular anthracycline-induced
cardiomyopathy complications in autologous HSCT survivors, however, also
remains of concern in which the cumulative incidence of CHF at 5 years after
HSCT of 4.8 %, increasing to 9.1 % at 15 years.[34] Overall, this cardiovascular
risk is 4.5-fold higher than that seen in the general population. Prior
anthracycline use and chest radiation also increases this risk.
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Treatment of cardiovascular complications of HSCT
First 100 days of HSCT
There are little specific data on how to manage systolic dysfunction in
patients undergoing HSCT; thus, its management during transplantation
should be the same as the general population with beta blockers and
ACE inhibitors per the American Heart Association and American Col-
lege of Cardiology guidelines.[35] Evidence that beta blockers (particu-
larly carvedilol) and ACE inhibitors are effective for preventing
anthracycline-induced cardiomyopathy provides further rationale for
this practice in oncology patients.[36–39] These medications have also
been shown to improve LVEF in subjects with anthracycline-induced
cardiomyopathy.[40]
Evaluation of cardiac systolic function by multiple gated acquisition
scan (MUGA), echocardiogram, or cardiac magnetic resonance imaging
(MRI) is a recommended part of a pre-transplantation evaluation.[41,
42] Attention to any signs of left ventricular dysfunction or premature
supraventricular complexes on screening electrocardiogram should be
reviewed carefully; consideration of preventative therapy with beta
blockers and angiotensin-converting enzyme (ACE) inhibitors should
be considered in this population given their higher risk for arrhythmias
during transplantation.[37, 38, 40, 43] Referral to a cardio-oncology
clinic, for those with any cardiovascular risk factors or prior cardiac
disease or arrhythmias, is recommended.[44•, 45, 46]
Treatment of long-term cardiac complications from HSCT
Given the increased burden for serious cardiovascular complications following
HSCT, a variety of long-term recommendations through the Children’s Oncol-
ogy Group and the Center for International Blood andMarrow Transplantation
have been developed for the treatment of cardiovascular risk factors in HSCT
survivors.[47–49] Given these guidelines differ from the cardiovascular screen-
ing recommendations of the general population as outlined by the United
States Services Preventative Task Force, we have provided an outline of these
recommendations below:
Lifestyle modifications
– As high as 30% of cancer survivors, particularly in the younger
aged population, smoke.[50] Patients should be counseled to
abstain from tobacco use. While tobacco use is associated with
secondary cancers, it is also a recognized inducer of cardiac
disease.
– Additional lifestylemodifications including a low fat diet, maintaining
a healthy weight, and regular exercise should be part of their
counseling.
– Additionally, the American College of Sports Medicine recommends at
least 150min of moderate exercise per week, regardless of age or
treatment used during HSCT.[51]
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Diabetes/impaired glucose tolerance testing
– With the 10-year cumulative incidence of diabetes being 918% in HSCT
survivors,[32] it is recommended that a fasting glucose be obtained every
3years after the age of 45years or earlier if blood pressure 9135/80mmHg.
– In childhood cancer survivors where the rates of metabolic syndrome
are even higher, the Children’s Oncology Group recommends a fasting
glucose every 2years after HSCT, particularly in those who received
cranial radiation or total body irradiation as part of their preparative
regimen.[48, 52]
Dyslipidemia (fasting lipids) testing
– With dyslipidemia occurring in 946% of HSCT survivors [32] and
many HSCT recipients having multiple cardiac risk factors, [5, 13•]
fasting lipids should be checked every 5years starting at age 35years for
men, age 45years for women, and earlier for those with other cardio-
vascular risk factors. For higher risk individuals who use tobacco, have
diabetes, hypertension, obesity, or a family history of cardiovascular
disease, screening should begin at age 20years.
– In childhood HSCT survivors, lipids should be checked every 2years
beginning 2years after HSCT, particularly in those who received cranial
radiation or total body irradiation.[13•]
Electrocardiogram screening
– While not recommended for the general population (UPSTF), screen-
ing with electrocardiogram should be considered for individuals with
risk factors for cardiovascular disease, namely amyloidosis, prior chest/
mediastinal radiation therapy, preexisting cardiovascular disease. With
more than 50% of patients with amyloidosis also having cardiac
involvement, this patient population is particularly at risk for arrhyth-
mias.[47, 49, 53] Monitoring electrocardiograms may be helpful. Ad-
ditionally, recipients of chest/mediastinal radiation have rates of car-
diac disease of 17% by age 35years.[54] With cardiac deaths being a
large cause of mortality in recipients of chest/mediastinal radiation,
screening electrocardiograms may be helpful [47, 49, 54, 55].
– For childhood HSCT survivors, baseline electrocardiogram is recom-
mended 2years after the completion of HSCT [13•].
Cardiac Imaging in Survivors
– In asymptomatic adults without any cardiac risk factors, cardiac im-
aging tests such as transthoracic echocardiography, carotid intima-
media thickness by ultrasound, stress echocardiography, and cardiac
magnetic resonance imaging are not recommended. In individuals,
however, with risk factors such as hypertension or diabetes, prior
chest radiation, history of amyloidosis, preexisting cardiac
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disease, baseline electrocardiogram, and transthoracic echocardi-
ography could be considered [49]. Stress echocardiography may
also be useful in those who have received prior cardiac medi-
astinal radiation [56].
– In children HSCT survivors, the Children’s Oncology Group has spe-
cific recommendations for interval of echocardiography based on age
of exposure, cumulative anthracycline dose exposure, and/or chest
radiotherapy [13•].
– The frequency of echocardiography screening based on age of cancer
diagnosis and treatment, receipt of radiation, and receipt of
anthracycline use is not known [41]; aggressive screening to monitor
for left ventricular dysfunction with subsequent early pharmacologic
intervention has been shown to be cost effective, although research
regarding the exact interval of screening is ongoing [57].
– Ongoing research as to the use of echocardiography with strain and
echocardiography with speckle tracking is ongoing [42, 58–60]. Simi-
larly, the use of cardiac MRI as a screening tool for cardiac fibrosis and
left ventricular remodeling is currently being studied.While not useful in
all HSCT survivors, it may be useful in select high-risk patients [41, 61].
– MUGA scan is discouraged given the use of radiation.
Other
– Screening for arterial disease with ankle brachial index and carotid
artery imaging is not recommended for the general HSCT population.
Consideration for carotid artery ultrasound imaging 10years post
HSCT should be considered for childhood HSCT survivors as well as
those treated with prior mantle radiation [13•, 49].
Pharmacologic Interventions
– There is little specific data on how to manage left ventricular dysfunc-
tion in patients undergoing HSCT; thus, its management post trans-
plantation should be the same as the general population with beta
blockers and ACE inhibitors per the American Heart Association and
American College of Cardiology guidelines [35]. Evidence that beta
blockers and ACE inhibitors are effective for treating anthracycline-
induced cardiomyopathy provides further rational for this practice in
these oncology patients [36–38].
– Similarly, aggressive management of hyperlipidemia and diabetes as
per the American Diabetes Association is recommended.
– Ongoing work suggests treating early left ventricular functionwith ACE
inhibitors or beta blockers may actually be cost-effective [57].
Cancer Survivorship Clinics
– Given the elevated risks of cardiac disease in HSCT as well as specific
recommendations for surveillance and follow-up care, consultation
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with a cancer survivorship clinic and receipt of a survivorship care plan
(SCP) may be useful in promoting knowledge of cardiac risk as well
screening recommendations [55, 62].
– Finally, for those individuals at highest risk for cardiac disease,
such as those with amyloidosis or who also have received prior
chest/mediastinal radiation who have also undergone HSCT,
referral to a cardio oncology clinic is extremely important. Col-
laboration between hematology/oncology and cardiology is of
critical importance in providing the best evidence based care for
recipients for HSCT [43, 44•].
Conclusion
Survivors of HSCT are at significant risk for cardiac disease and cardiac compli-
cations. While there may be cardiac complications during the acute period of
HSCT, long-term survivors remain at risk for cardiovascular disease at a rate at
least fourfold higher than the general population. Aggressive screening for
cardiac risk factors such as diabetes, hypertension, and hyperlipidemia is war-
ranted as is early and aggressive treatment of left ventricular dysfunction.
Collaboration between hematology/oncology and cardiology through a
cardio-oncology clinic is an optimal way to help manage these patients.
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